Browse ADCYAP1R1

Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00002 7 transmembrane receptor (Secretin family)
PF02793 Hormone receptor domain
Function

This is a receptor for PACAP-27 and PACAP-38. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. May regulate the release of adrenocorticotropin, luteinizing hormone, growth hormone, prolactin, epinephrine, and catecholamine. May play a role in spermatogenesis and sperm motility. Causes smooth muscle relaxation and secretion in the gastrointestinal tract.

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006109 regulation of carbohydrate metabolic process
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007202 activation of phospholipase C activity
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007283 spermatogenesis
GO:0007548 sex differentiation
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010522 regulation of calcium ion transport into cytosol
GO:0010524 positive regulation of calcium ion transport into cytosol
GO:0010675 regulation of cellular carbohydrate metabolic process
GO:0010676 positive regulation of cellular carbohydrate metabolic process
GO:0010863 positive regulation of phospholipase C activity
GO:0010919 regulation of inositol phosphate biosynthetic process
GO:0010959 regulation of metal ion transport
GO:0016051 carbohydrate biosynthetic process
GO:0019751 polyol metabolic process
GO:0019932 second-messenger-mediated signaling
GO:0019933 cAMP-mediated signaling
GO:0019935 cyclic-nucleotide-mediated signaling
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030819 positive regulation of cAMP biosynthetic process
GO:0032355 response to estradiol
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0032958 inositol phosphate biosynthetic process
GO:0033555 multicellular organismal response to stress
GO:0042493 response to drug
GO:0043255 regulation of carbohydrate biosynthetic process
GO:0043270 positive regulation of ion transport
GO:0043647 inositol phosphate metabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044283 small molecule biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0045137 development of primary sexual characteristics
GO:0045471 response to ethanol
GO:0045913 positive regulation of carbohydrate metabolic process
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046165 alcohol biosynthetic process
GO:0046173 polyol biosynthetic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0048232 male gamete generation
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0052652 cyclic purine nucleotide metabolic process
GO:0055074 calcium ion homeostasis
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0060732 positive regulation of inositol phosphate biosynthetic process
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0072522 purine-containing compound biosynthetic process
GO:0097305 response to alcohol
GO:1900274 regulation of phospholipase C activity
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1902930 regulation of alcohol biosynthetic process
GO:1902932 positive regulation of alcohol biosynthetic process
GO:2000021 regulation of ion homeostasis
Molecular Function GO:0004999 vasoactive intestinal polypeptide receptor activity
GO:0008179 adenylate cyclase binding
GO:0030306 ADP-ribosylation factor binding
GO:0031267 small GTPase binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042923 neuropeptide binding
GO:0051020 GTPase binding
Cellular Component GO:0005791 rough endoplasmic reticulum
GO:0005901 caveola
GO:0005923 bicellular tight junction
GO:0043235 receptor complex
GO:0043296 apical junction complex
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0070160 occluding junction
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04024 cAMP signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
hsa04713 Circadian entrainment
hsa04911 Insulin secretion
Reactome R-HSA-187015: Activation of TRKA receptors
R-HSA-373080: Class B/2 (Secretin family receptors)
R-HSA-418555: G alpha (s) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-420092: Glucagon-type ligand receptors
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-187024: NGF-independant TRKA activation
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-166520: Signalling by NGF
Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ADCYAP1R1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ADCYAP1R1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ADCYAP1R1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6260.121
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.470.684
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8280.528
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4540.486
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1850.846
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8190.417
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5810.308
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2790.0914
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0570.836
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ADCYAP1R1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.81.413.40.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117190190.113
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADCYAP1R1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADCYAP1R1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADCYAP1R1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADCYAP1R1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ADCYAP1R1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ADCYAP1R1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolADCYAP1R1
Nameadenylate cyclase activating polypeptide 1 (pituitary) receptor type I
Aliases PACAPR; PAC1R; PACAP receptor 1; PACAPRI; PACAP type I receptor; PACAP-R1; pituitary adenylate cyclase activ ......
Chromosomal Location7p14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ADCYAP1R1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.